We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Use of intermittently scanned continuous glucose monitoring in young people with high‐risk type 1 diabetes—Extension phase outcomes following a 6‐month randomized control trial.
- Authors
Rose, Shelley; Styles, Sara E.; Wiltshire, Esko J.; Stanley, James; Galland, Barbara C.; de Bock, Martin I.; Tomlinson, Paul A.; Rayns, Jenny A.; MacKenzie, Karen E.; Wheeler, Benjamin J.
- Abstract
Aims: To describe the impact of a 12‐month intervention using intermittently scanned continuous glucose monitoring (isCGM) on glycaemic control and glucose test frequency in adolescents and young adults with type 1 diabetes (T1D) and high‐risk glycaemic control (HbA1c ≥75 mmol/mol [≥9.0%]). Methods: In total, 64 young people (aged 13–20 years, 16.6 ± 2.1 years; 48% female; 41% Māori or Pacific ethnicity; mean diabetes duration 7.5 ± 3.8 years) with T1D were enrolled in a 6‐month, randomized, parallel‐group study comparing glycaemic outcomes from the isCGM intervention (n = 33) to self monitoring blood glucose (SMBG) controls (n = 31). In this 6‐month extension phase, both groups received isCGM; HbA1c, glucose time‐in‐range (TIR), and combined glucose test frequency were assessed at 9 and 12 months. Results: At 12 months, the mean difference in HbA1c from baseline was −4 mmol/mol [−0.4%] (95% confidence interval, CI: −8, 1 mmol/mol [−0.8, 0.1%]; p = 0.14) in the isCGM intervention group, and −7 mmol/mol [−0.7%] (95% CI: −16, 1 mmol/mol [−1.5, 0.1%]; p = 0.08) in the SMBG control group. No participants achieved ≥70% glucose TIR (3.9–10.0 mmol/L). The isCGM intervention group mean rate of daily glucose testing was highest at 9 months, 2.4 times baseline rates (p < 0.001), then returned to baseline by 12 months (incidence rate ratio = 1.4; 95% CI: 0.9, 2.1; p = 0.091). Conclusions: The use of isCGM in young people with high‐risk T1D resulted in transient improvements in HbA1c and glucose monitoring over a 9‐month time frame; however, benefits were not sustained to 12 months.
- Subjects
GLYCOSYLATED hemoglobin; CONFIDENCE intervals; BLOOD sugar monitoring; GLYCEMIC control; TYPE 1 diabetes; BLOOD sugar; TREATMENT duration; TREATMENT effectiveness; RANDOMIZED controlled trials; COMPARATIVE studies; DESCRIPTIVE statistics
- Publication
Diabetic Medicine, 2022, Vol 39, Issue 5, p1
- ISSN
0742-3071
- Publication type
Article
- DOI
10.1111/dme.14756